Stratos Genomics, a US-based DNA sequencing technology developer backed by pharmaceutical firm Roche, has secured $20m in funding from venture capital firm Fisk Ventures.
Spun off from technology development services provider Stratos Group in 2007, Stratos Genomics is developing a DNA sequencing process called Sequencing By Expansion, which encodes the sequence of a DNA molecule into a measurable surrogate it calls an Xpandomer.
The funding will be used to finalise development of the company’s technology as it prepares for commercial release.
Fisk Ventures had previously taken part in the $30m series B round closed by Stratos in 2015, investing alongside Roche’s strategic investment arm, Roche Ventures. Stratos has disclosed approximately $58m of equity funding, including $4m in a 2010 round featuring Stratos Group and Fisk Ventures.
Mark Kokoris, president and chief executive of Stratos Genomics, said: “We are excited that our vision of introducing a transformative next-generation sequencing platform to the healthcare and research markets is approaching realisation.”